Age, Biography and Wiki
Sandip Basu was born on 1971 in Indian, is an Indian physician of Nuclear Medicine. Discover Sandip Basu's Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is he in this year and how he spends money? Also learn how he earned most of networth at the age of 53 years old?
| Popular As |
N/A |
| Occupation |
N/A |
| Age |
53 years old |
| Zodiac Sign |
N/A |
| Born |
|
| Birthday |
|
| Birthplace |
N/A |
| Nationality |
|
We recommend you to check the complete list of Famous People born on .
He is a member of famous Physician with the age 53 years old group.
Sandip Basu Height, Weight & Measurements
At 53 years old, Sandip Basu height not available right now. We will update Sandip Basu's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.
| Physical Status |
| Height |
Not Available |
| Weight |
Not Available |
| Body Measurements |
Not Available |
| Eye Color |
Not Available |
| Hair Color |
Not Available |
Dating & Relationship status
He is currently single. He is not dating anyone. We don't have much information about He's past relationship and any previous engaged. According to our Database, He has no children.
| Family |
| Parents |
Not Available |
| Wife |
Not Available |
| Sibling |
Not Available |
| Children |
Not Available |
Sandip Basu Net Worth
His net worth has been growing significantly in 2023-2024. So, how much is Sandip Basu worth at the age of 53 years old? Sandip Basu’s income source is mostly from being a successful Physician. He is from . We have estimated Sandip Basu's net worth, money, salary, income, and assets.
| Net Worth in 2024 |
$1 Million - $5 Million |
| Salary in 2024 |
Under Review |
| Net Worth in 2023 |
Pending |
| Salary in 2023 |
Under Review |
| House |
Not Available |
| Cars |
Not Available |
| Source of Income |
Physician |
Sandip Basu Social Network
| Instagram |
|
| Linkedin |
|
| Twitter |
|
| Facebook |
|
| Wikipedia |
|
| Imdb |
|
Timeline
Sandip Basu is an Indian physician of Nuclear Medicine and the Head, Nuclear Medicine Academic Program at the Radiation Medicine Centre (Bhabha Atomic Research Centre).
He is also the Dean-Academic (Health-Sciences), BARC at Homi Bhabha National Institute and is known for his services and research in Nuclear Medicine, particularly on Positron emission tomography diagnostics and Targeted Radionuclide Therapy in Cancer.
Between 2010 and 2020, Dr. Basu was instrumental in developing a large-volume clinical PRRT service in the centre by the joint efforts of Radiation Medicine Centre (RMC), Bhabha Atomic Research Centre (BARC), and Tata Memorial Hospital (TMH) at the TMH-RMC premises, delivering over 4,000 [177Lu]Lu-DOTATATE therapies for patients with metastatic/advanced neuroendocrine neoplasms and related malignancies making this the largest PRRT set-up in the country, an exemplar of successful PRRT programme employing indigenous 177Lutetium production at BARC and resources.
The Society of Nuclear Medicine and Molecular Imaging selected him for the Alavi-Mandell Award in 2010.
The Council of Scientific and Industrial Research, the apex agency of the Government of India for scientific research, awarded him the Shanti Swarup Bhatnagar Prize for Science and Technology, one of the highest Indian science awards for his contributions to Nuclear Medicine in 2012.
Sandip Basu, is a Professor of Nuclear Medicine at the Radiation Medicine Centre, and Head, Nuclear Medicine Academic Programme, affiliated to the Health Sciences, BARC.
He also serves as the dean-academics (Health Sciences), BARC at Homi Bhabha National Institute of the Department of Atomic Energy.
He pursues his clinical patient services, academics and research interests at the Radiation Medicine Centre Bhabha Atomic Research Centre housed at Tata Memorial Hospital Annexe Building at Parel, Mumbai.
He is known for his clinical and applied research in the field of Nuclear Medicine, especially on positron emission tomography-based diagnostics and Targeted Radionuclide therapy.
One major area of his research interests and clinical work has been the integration of functional radionuclide imaging and targeted radionuclide treatment which assisted in developing personalized management model and providing individualized treatment to patients of cancer.
His studies have been documented by way of a number of articles of which many have been listed by online article repositories such as Google Scholar and ResearchGate.
Besides, he has guest-edited six books viz.
Breast Cancer Imaging I: Number 3, Breast Cancer Imaging II: Pet Clinics, Radiation Therapy Planning with PET: Number 2, Modern Quantitative Techniques for PET, PET Imaging of Brain Tumors, An Issue of PET Clinics and PET-Based Molecular Imaging in Evolving Personalized Management Design, An Issue of PET Clinics and has contributed chapters to books published by others.
Basu served as the national project coordinator of the IAEA-Regional Co-operative Agreement project at Bhabha Atomic Energy Centre on Strengthening the Applications of Nuclear Medicine in the Management of Cardiovascular Diseases.
He serves as a member of the editorial boards of a number of journals including European Journal of Nuclear Medicine and Molecular Imaging, Nuclear Medicine Communications and Hellenic journal of Nuclear Medicine.
He is also a former editor of World Journal of Radiology.
He has been an author of more than 400 peer-reviewed papers and delivered several invited speeches in national/international conferences and symposiums.
In his capacity as the Dean-Academics, Medical and Health Sciences, BARC, Dr Basu took pivotal role in initiating the M.D. (Nuclear Medicine) course for doctors and the M.Sc.(Nuclear Medicine and Molecular Imaging Technology) and M.Sc.
(Hospital Radiopharmacy) courses for science graduates, at the Radiation Medicine Centre (BARC) under the aegis of HBNI University, aimed at developing trained manpower in the field of Nuclear Medicine.
(Hospital Radiopharmacy) course at the Centre was first of its kind in India, providing structured training in the subject.
The Council of Scientific and Industrial Research awarded Basu the Shanti Swarup Bhatnagar Prize, one of the highest Indian science awards in 2012.
Since 2017, he steered the development of [68Ga]Ga-/[177Lu]Lu-PSMA-based theranostics and peptide receptor radioligand therapy (PRLT) in metastatic castration resistant prostate carcinoma (mCRPC) patients in the centre.
Dr. Basu was recipient of the DAE Homi Bhabha Science and Technology Award 2017 and the Homi Bhabha Memorial Oration 2019 at the 51st Annual Meeting of the Society of Nuclear Medicine India.
